NI
ALXN

Numeric Investors’s Alexion Pharmaceuticals ALXN Stock Holding History

Numeric Investors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$8.81M Buy
73,700
+62,700
+570% +$7.64M 0.06% 294
2017
Q3 		$1.54M Buy
11,000
+5,800
+112% +$788K 0.01% 654
2017
Q2 		$633K Sell
5,200
-4,100
-44% -$477K 0.01% 763
2017
Q1 		$1.13M Buy
9,300
+6,300
+210% +$812K 0.01% 614
2016
Q4 		$367K Buy
+3,000
New +$367K ﹤0.01% 875
2016
Q3 		– Sell
-2,400
Closed -$280K – 1246
2016
Q2 		$280K Sell
2,400
-200
-8% -$28.4K ﹤0.01% 901
2016
Q1 		$362K Buy
+2,600
New +$382K ﹤0.01% 809
2015
Q2 		– Sell
-43,740
Closed -$7.58M – 1128
2015
Q1 		$7.58M Buy
43,740
+1,200
+3% +$217K 0.09% 205
2014
Q4 		$7.87M Buy
42,540
+25,530
+150% +$4.73M 0.1% 179
2014
Q3 		$2.82M Sell
17,010
-80,540
-83% -$13.2M 0.04% 292
2014
Q2 		$15.2M Buy
97,550
+94,090
+2,719% +$14.9M 0.23% 115
2014
Q1 		$526K Buy
+3,460
New +$550K 0.01% 579

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Numeric Investors's ALXN Position: Q4 2017 in Review

Numeric Investors increased its Alexion Pharmaceuticals (ALXN) stake by 570% in Q4 2017, buying an estimated $7.64M and bringing the position to 73,700 shares worth $8.81M. The position accounts for 0.06% of the portfolio, ranked #294.

Numeric Investors first reported a position in ALXN in Q1 2014 and has held it in 12 quarters since. The position peaked at $15.2M in Q2 2014. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Numeric Investors held 73,700 shares of Alexion Pharmaceuticals worth $8.81M as of Q4 2017.
  • Numeric Investors bought 62,700 Alexion Pharmaceuticals shares in Q4 2017, an estimated $7.64M.
  • Alexion Pharmaceuticals made up 0.06% of Numeric Investors's portfolio in Q4 2017, its #294 holding.
  • Numeric Investors first reported a position in Alexion Pharmaceuticals in Q1 2014 and has held it in 12 quarters since.
  • Numeric Investors's Alexion Pharmaceuticals position peaked at $15.2M in Q2 2014.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Numeric Investors's 13F filing for Q4 2017, filed 14 Feb 2018.